Canada - English
Canada - Français
New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score® results of 0 to 25.
For a refined risk estimateof local recurrence
The Oncotype DX GPS assay is fully covered by Medicare for localized prostate cancer patients.
Nuclear-specific vs. nuclear-agnostic AR-V7 testing
Help Stage II colon cancer patients understand the power of genomics
Your Oncotype DX score can help you decide.
Oncotype DX has helped thousands of women find out.
When Dan's Colon Recurrence Score came back low, he decided against chemotherapy.
"Adjuvant chemotherapy may now be guided with an unprecedented level of evidence and precision" said lead author Joseph A. Sparano, MD. "The 21-gene assay ... [can] identify the 70% of women with no chemotherapy benefit, and the others where chemotherapy may be life-saving." Know with confidence who will benefit from chemotherapy and who will not.1-4
The largest randomized adjuvant breast cancer trial ever conducted, the Trial Assigning IndividuaLized Options for Treatment (Rx) (TAILORx) was independently led by ECOG-ACRIN Cancer Research Group with sponsorship from the National Cancer Institute.
As presented at ASCO 2019, a new analysis of TAILORx confirms the original, definitive conclusions reported previously with additional detail on clinical risk, focusing on patients with early-stage breast cancer who are age 50 years or younger.
As presented at ESMO 2019, a new, secondary analysis of TAILORx, highlighted clinical outcomes in patients with a Recurrence Score result of 26‐100. This new analysis reinforces the definitive results of TAILORx, that only the Oncotype DX Breast Recurrence Score test identifies patients who will and will not benefit from chemotherapy.
Participating cancer research groups included the Alliance for Clinical Trials in Oncology, NCIC-Clinical Trials Group, NRG Oncology, and SWOG.
*Driven largely by the higher likelihood of having an event in the cohort with an RS 26–100.
In an exploratory analysis, TAILORx showed a chemotherapy benefit for early breast cancer patients aged 50 or younger with RS scores of 16–25. This subgroup represents about 8% of patients.5
For the great majority of early-stage (HR+, HER2-, N0) breast cancer patients aged 50+, the TAILORx trial results predict no statistically significant benefit from chemotherapy.
For patients with RS results from 26–100, there is a substantial benefit from chemotherapy.4
As with older patients, for those up to age 50 with a Recurrence Score result of 0–15, TAILORx predicts no benefit in adding chemotherapy to endocrine therapy.1
In these younger patients, an exploratory analysis of TAILORx predicts a small (~1.6%) chemotherapy benefit for patients with RS results from 16–20, and a modest (~6.5%) chemotherapy benefit for patients with RS results from 21–25.
Together, these two subgroups comprise about 8% of patients.5
As with patients over age 50, younger patients with RS results from 26–100 receive a substantial benefit from chemotherapy.4
The landmark TAILORx trial is not the only large, randomized clinical trial supporting the use of the Breast Recurrence Score® report.
The TAILORx trial reports 9-year outcomes for >10,000 women with early breast cancer. Over 1,000 trial sites in 6 countries participated.
ASCO = American Society of Clinical Oncology
ECOG-ACRIN = Eastern Cooperative Oncology Group - American College of Radiology and Imaging Network
NIH = National Institutes of Health
NRG = Non-profit Research Group
RS = Recurrence Score
SWOG = Southwest Oncology Group
TAILORx = A Clinical Trial Assigning IndividuaLized Options for Treatment (Rx)
The TAILORx trial was conducted independently by the ECOG-ACRIN Cancer Research Group.
Have questions? We're here to help.